John Helou was the President of Pfizer Canada ULC. for 8 years and retired on February 29th, 2020
John began his career as a Chemical Engineer with Dupont Canada in 1980. He transitioned to Dupont’s pharmaceutical business five years later and went on to assume positions of increasing responsibility in the Canadian subsidiary and the corporate headquarters in the United States. John’s experience at Dupont spanned Sales, Strategic Planning, Business Development and Marketing within the Canadian subsidiary and later at the US and Global level. In 1997, John accepted the position of General Manager to set up Agouron Canada, a start-up biotech company specializing in HIV and Oncology. Following the transfer of Agouron’s business operations to Pfizer Canada in 2003, John was appointed Director, Sales for Pfizer Canada’s Specialty Business.
In 2006, he was appointed Vice President of the Public Affairs and Stakeholder Relations division where he oversaw five distinct departments with diverse responsibilities, including corporate communications, consumer communications, health policy and strategy, patient access and stakeholder relations.
John was actively involved in several industry, business and community associations. He was Chair and later Vice-Chair to the Board of Directors of Innovative Medicines Canada, a member of the Board of BIOTECanada, a member of the Business Council of Canada and Co-chair, West-Island Community Shares 2017-2018 annual fundraising campaign. He was formerly a Board Member of the Advanced Coronary Treatment (ACT) Foundation.
In 2014, John was inducted into the Canadian Healthcare Marketing Hall of Fame.
John holds a chemical engineering degree from the University of Toronto. He recently became a grandfather. In his spare time, he enjoys cycling and golf.
Agenda: Day 1 Oct 5, 2020
Agenda: Day 2 Oct 6, 2020
FIRESIDE CHAT: ELECTION 2021 POST- MORTEM
The More Things Don’t Change, The More More They Stay The Same?
Now that an ‘unnecessary’ election that had polls at a virtual tie between the Liberal and PC parties at the end is over, what’s next? Join us for this critical briefing recapping the election results overall, and specifically what this will mean to the future of a Health and Life Sciences Strategy for all Canadians to benefit from. Dialogue with your peers and expand your political acumen from an expert in Canadian politics and a long-time industry insider to:
- Better understand how the Coronavirus Delta variant, rapid changes in vaccine information and other pandemic factors may have influenced election results and what that indicates for future funding opportunities;
- Expand your organization’s potential in whatever role the health and life sciences industry can play in a post-pandemic economic recovery for Canada;
- Position your organization in the best light possible for a future of profitable growth and favourable consumer opinion.
Benefit from an insider’s perspective at this can’t miss session!